Mon, Jan 26, 2015, 11:50 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, Inc. Message Board

  • bearofbleecker bearofbleecker Nov 5, 2012 1:35 PM Flag

    ASH abstract on elotuzumab.

    Working my way through the abstracts released today for presentation at the ASH convention in December, I note that in addition to those substantiating the activity of carfilzomib in multiple myeloma, there is an interesting one on ONXX's monoclonal antibody, elotuzumab. (Carfilzomib is a proteasome inhibitor.) This also seems to be highly effective in MM patients, producing a 96% response rate after 4 cycles of treatment. Since I believe that this would be the first monoclonal antibody for this disease, this seems to my inexpert eye that it may be even more significant than carfilzomib, which has well-established competition in Velcade.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Okay, now that I've untangled my notes, I see that this is really a Bristol-Myers drug. The abstract which interested me relative to carfilzomib (Kyrpolis) was one which suggested that in addition to activity vs MM, it may also have broad scale usage in a whole range of auto-immune disease, since it seems to activate T-cells.

124.700.0000(0.00%)Sep 30 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.